Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ionis Pharmaceuticals (NQ: IONS ) 42.39 -5.94 (-12.29%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Ionis Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 Next > Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session Today 8:32 EDT Via Benzinga Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket Today 6:41 EDT Via Benzinga What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals August 26, 2024 Via Benzinga 12 Analysts Have This To Say About Ionis Pharmaceuticals August 02, 2024 Via Benzinga Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst July 22, 2024 Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety... Via Benzinga The Latest Analyst Ratings For Ionis Pharmaceuticals July 16, 2024 Via Benzinga Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts June 27, 2024 Via Benzinga Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong July 22, 2024 Biogen previously decided against opting into Ionis' Angelman program. Via Investor's Business Daily RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session June 24, 2024 Via Benzinga Masters In Trading - Saturday, June 22 June 22, 2024 In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. Via Talk Markets Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) June 03, 2024 Via Benzinga Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile May 31, 2024 Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year. Via Benzinga Exposures Product Safety The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals May 08, 2024 Via Benzinga The Latest Analyst Ratings For Ionis Pharmaceuticals April 09, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals February 22, 2024 Via Benzinga Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder May 31, 2024 The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS. Via Benzinga Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another May 16, 2024 Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes. Via Benzinga The 3 Most Undervalued Pharma Stocks to Buy in May 2024 May 09, 2024 Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks. Via InvestorPlace IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 May 07, 2024 IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows March 13, 2024 Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with... Via Benzinga Earnings Scheduled For February 21, 2024 February 21, 2024 Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. Via Benzinga Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts January 18, 2024 Via Benzinga JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know February 01, 2024 Via Benzinga Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines January 31, 2024 Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. Via Benzinga Exposures Product Safety Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study January 22, 2024 Phase 3 OASIS-HAE study results by Ionis Pharmaceuticals Donidalorsen shows remarkable efficacy, safety, and plans for FDA submission. Via Benzinga Exposures Product Safety Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily 2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs January 04, 2024 A recent report from Tema ETFs, a leader in active exchange-traded funds (ETFs), offers a window into six emerging long-term megatrends. Its analysis provides a detailed account of evolving sectors,... Via Benzinga Topics ETFs 10 Health Care Stocks Whale Activity In Today's Session January 02, 2024 Via Benzinga 3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies December 27, 2023 These future trillion dollar stocks can solidify portfolio growth for long-term investors. Discover the stocks to buy in 2024. Via InvestorPlace Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential December 22, 2023 Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am Via Benzinga Exposures Product Safety < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.